膀胱癌におけるジヒドロピリミジン脱水素酵素の欠損がゲムシタビンに対する感受性を促進する

1. Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 1–15 (2020).

2. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–477 (2006).

3. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy lone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).

4. Griffiths, G. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: Long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).

5. von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602–4608 (2005).

6. von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068–3077 (2000).

7. Teo, M. Y. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinumtreated advanced urothelial carcinoma. Clin. Cancer Res. 23, 3610–3618 (2017).

8. Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959–967 (2015).

9. van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140–1153 (2014).

10. Maring, J. G., Groen, H. J. M., Wachters, F. M., Uges, D. R. A. & de Vries, E. G. E. Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J. 5, 226–243 (2005).

11. Sun, Y., Wang, J. & Hao, K. A pharmacodynamic evaluation of the anti-hepatocellular carcinoma compound 4-n carcocenzoxygemcitabine (Cbz-dFdC). Molecules 25, 2218 (2020).

12. Kurata, N. et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int. J. Oncol. 39, 473–482 (2011).

13. Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544–554 (2017).

14. Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 17, 540.e25-556.e25 (2017).

15. Murakawa, M. et al. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapy. Oncol. Lett. 14, 1505–1511 (2017).

16. Ide, H. et al. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. BMC Cancer 12, 420 (2012).

17. Narimatsu, A. et al. 5-Fluorouracil-based adjuvant chemotherapy improves the clinical outcomes of patients with lymphovascular invasion of upper urinary tract cancer and low expression of dihydropyrimidine dehydrogenase. Oncol. Lett. 17, 4429–4436 (2019).

18. Elander, N. O. et al. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Br. J. Cancer. 118, 947–954 (2018).

19. Hishinuma, E. et al. Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals. Drug Metab. Dispos. 46, 1083–1090 (2018).

20. Vivaldi, C. et al. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics J. 21, 233–242 (2021).

21. Matsumoto, T. et al. Genomic characteristics revealed by targeted exon sequencing of testicular germ cell tumors in Japanese men. Int. J. Urol. 28, 40–46 (2021).

22. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat Methods. 7, 248–249 (2010).

23. Cerami, E. et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).

24. Liu, J. et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(400), e11-416.e11 (2018).

25. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. 102, 15545–15550 (2005).

26. Amamoto, R. et al. Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate specific antigen relapse time after radical prostatectomy. Cancer Sci. 102, 639–647 (2011).

27. Hayashi, T. et al. Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer. J. Urol. 194, 1120–1131 (2015).

28. Matsumoto, T. et al. Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: Importance of stem cell plasticity. Oncogenesis. 6, 397 (2017).

29. Zala, D. et al. Vesicular glycolysis provides on-board energy for fast axonal transport. Cell 152, 479–491 (2013).

30. Uchiumi, T. et al. ERAL1 is associated with mitochondrial ribosome and elimination of ERAL1 leads to mitochondrial dysfunction and growth retardation. Nucleic Acids Res. 38, 5554–5568 (2010).

31. Sasaki, K. et al. p32 is required for appropriate interleukin-6 production upon LPS stimulation and protects mice from endotoxin shock. EBioMedicine 20, 161–172 (2017).

32. Setoyama, D., Fujimura, Y. & Miura, D. Metabolomics reveals that carnitine palmitoyltransferase-1 is a novel target for oxidative inactivation in human cells. Genes Cell. 18, 1107–1119 (2013).

33. Hsiao, J. J., Potter, O. G., Chu, T. W. & Yin, H. Improved LC/MS methods for the analysis of metal-sensitive nalytes using medronic acid as a mobile phase additive. Anal. Chem. 90, 9457–9464 (2018).

34. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458 (2013).